Unity Biotechnology's better-than-expected Q4 2023 earnings report, with a loss per share significantly below analyst expectations and a notable improvement from the previous year, is likely to positively impact investor sentiment and the stock price in the short term. The substantial beat on estimates and year-over-year improvement highlight the company's potential for reduced losses and possibly a path to profitability, which can be seen as positive signals by the market.